We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSUMM.L Share News (SUMM)

  • There is currently no data for SUMM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Thursday broker round-up UPDATE

Thu, 22nd Aug 2013 07:25

Aggreko: RBC Capital reduces target price from 1850p to 1680p, while its neutral rating remains unchanged.Aviva: JP Morgan raises target price from 393p to 436p and retains an overweight rating.BHP Billiton: Canaccord Genuity takes target price from 1950p to 2050p maintaining a hold recommendation.Cairn Energy: RBC Capital moves target price from 440p to 450p and reiterates its outperform rating.Cropper (James): Westhouse Securities ups target price from 300p to 350p, while downgrading to add.Faroe Petroleum: Liberum Capital lowers target price from 188p to 183p, while leaving its buy recommendation unchanged.Ferrexpo: Cantor Fitzgerald reduces target price from 373p to 290p, but stays with its buy recommendation.Glencore Xstrata: JP Morgan cuts target price from 410p to 390p retaining its overweight rating.Hikma Pharmaceuticals: Jefferies ups target price from 1200p to 1250p and keeps a buy recommendation.Hochschild Mining: Westhouse Securities increases target price from 150p to 200p and reiterates a neutral rating. JP Morgan moves target price from 75p to 80p, while keeping an underweight rating. Citi shifts target price from 133p to 132p and maintains its sell recommendation. RBC Capital ups target price from 220p to 260p and stays with its neutral rating.IMI: Investec places both its target price (prev.: 1350p) and its hold recommendation under review.Intertek Group: Credit Suisse reduces target price from 3850p to 3600p, while retaining an outperform rating.IP Group: Numis lowers target price from 129p to 124p, while its hold recommendation remains unchanged.John Wood Group: JP Morgan cuts target price from 963p to 951p and stays with its neutral rating. Liberum Capital reduces target price from 892p to 874p.Legal & General Group: Morgan Stanley moves target price from 184p to 192p and maintains an equal-weight rating.Lloyds Banking Group: Jefferies shifts target price from 65p to 69p reiterating a hold recommendation.Sportech: Investec lowers target price from 110p to 105p and leaves its buy recommendation unaltered.Stagecoach Group: Deutsche Bank raises target price from 330p to 350p staying with its buy recommendation.Summit Corporation: N+1 Singer shifts target price from 8.80p to 10.70p keeping its buy recommendation.Vitec Group: Investec increases target price from 740 to 810p and retains a buy recommendation.Wolseley: UBS upgrades from neutral to buy with a target price of 3500p.
More News
24 Feb 2020 10:52

Summit Therapeutics Delists In London As Focus Shifts To US

Summit Therapeutics Delists In London As Focus Shifts To US

Read more
24 Jan 2020 12:49

Summit Therapeutics Chief Operating & Medical Officer Roblin Resigns

Summit Therapeutics Chief Operating & Medical Officer Roblin Resigns

Read more
23 Jan 2020 16:47

Summit Gets More Funding For C. Difficile Infection Treatment

Summit Gets More Funding For C. Difficile Infection Treatment

Read more
24 Dec 2019 10:27

Summit Therapeutics Shuffles Board After Raising USD50 Million

Summit Therapeutics Shuffles Board After Raising USD50 Million

Read more
24 Dec 2019 09:09

Summit Therapeutics raises $40m, completes board restructuring

(Sharecast News) - Antibiotic innovation company Summit Therapeutics raised $50.0m on Tuesday by way of a subscription and placing of new ordinary shares and warrants.

Read more
17 Dec 2019 13:20

Summit Therapeutics Reports Decrease In Revenue In Third Quarter

Summit Therapeutics Reports Decrease In Revenue In Third Quarter

Read more
6 Dec 2019 13:34

Summit Therapeutics Plans Wholesale Changes As It Raises Cash

Summit Therapeutics Plans Wholesale Changes As It Raises Cash

Read more
6 Dec 2019 08:56

Summit Therapeutics raising $50m, plans to delist from AIM

(Sharecast News) - Antibiotic innovation company Summit Therapeutics announced a proposed fundraising of about $50m through a subscription and placing of new ordinary shares and warrants to existing investors on Friday, which would be subject to certain shareholder approvals being obtained and certain customary closing conditions being satisfied.

Read more
11 Oct 2019 12:53

Summit Therapeutics Sinks To Interim Loss On Ezutromid Discontinuation

Summit Therapeutics Sinks To Interim Loss On Ezutromid Discontinuation

Read more
7 Oct 2019 13:23

Summit Therapeutics Posts Explanation For Ridinilazole Trial In C Diff

Summit Therapeutics Posts Explanation For Ridinilazole Trial In C Diff

Read more
3 Oct 2019 14:23

Summit Therapeutics Reports Positive Ridinilazole Trial Results

Summit Therapeutics Reports Positive Ridinilazole Trial Results

Read more
17 Jul 2019 13:48

Summit Therapeutics New Antibiotic Shows Potential Against Gonorrhoea

(Alliance News) - Summit Therapeutics PLC on Wednesday highlighted the potential of its preclinical new class antibiotic, SMT-571, to treat gonorrhoea, at the STI & HIV World Congress in said

Read more
12 Jun 2019 13:54

Summit Therapeutics Narrows First Quarter Loss As Expenses Drop

(Alliance News) - Summit Therapeutics on Wednesday said its loss narrowed in its financial first quarter due to an increase in other operating income and a reduction in operating which develops a

Read more
15 Apr 2019 11:26

Summit Therapeutics DDS-04 Series Antibiotic Cures Infection In Study

LONDON (Alliance News) - Summit Therapeutics PLC on Monday presented proof of concept data for its DDS-04 series of antibiotics targeting Enterobacteriaceae, a family of bacteria that cause severe

Read more
15 Apr 2019 10:16

Summit Therapeutics upbeat on latest DDS-04 data

(Sharecast News) - Antibiotic innovation firm Summit Therapeutics reported on in vivo proof-of-concept data for the DDS-04 series of new mechanism antibiotics targeting enterobacteriaceae on Monday, having presented them at the 29th European Congress of Clinical Microbiology and Infectious Diseases in Amsterdam.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.